GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

GLP-1A

Company
Stanford University
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for GLP-1A and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07625202

    Creatine Supplementation During GLP-1a Therapy

    Not yet reported University of Saskatchewan 40 participants Est. completion 2027-12-31 1 site
    Other conditions: Sarcopenia
    View official trial listing →
  • Completed NCT NCT04200625

    Semaglutide vs Dulaglutide on Epicardial Adipose Tissue

    University of Miami 80 participants Est. completion 2019-12-09 1 site
    Other conditions: Epicardial Fat
    View official trial listing →
  • Completed NCT NCT04779697

    GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight

    Not yet reported Yale University 96 participants Est. completion 2024-11-19 1 site Added to GLP-1
    Other conditions: Obesity
    View official trial listing →
  • Status unknown NCT NCT05751720

    Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue

    Not yet reported, Not yet reported Dr Adnan Agha 30 participants Est. completion 2025-02 1 site Added to GLP-1
    Type 2 diabetes Other conditions: Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Liver Fat
    View official trial listing →
  • Not yet recruiting NCT NCT06682351

    Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention

    Not yet reported Stanford University 200 participants Est. completion 2027-12 1 site Stand-alone
    Type 2 diabetesPrediabetes
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.